z-logo
open-access-imgOpen Access
Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies
Author(s) -
Xing Zhu,
Dhiraj Mannar,
Shanti Swaroop Srivastava,
Alison Berezuk,
JeanPhilippe Demers,
James W. Saville,
Karoline Leopold,
Wei Li,
Dimiter S. Dimitrov,
K.S. Tuttle,
Shaoyu Zhou,
Sagar Chittori,
Sriram Subramaniam
Publication year - 2021
Publication title -
plos biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.127
H-Index - 271
eISSN - 1545-7885
pISSN - 1544-9173
DOI - 10.1371/journal.pbio.3001237
Subject(s) - biology , neutralization , mutant , infectivity , epitope , mutation , neutralizing antibody , cryo electron microscopy , antibody , protein structure , spike (software development) , virology , spike protein , plasma protein binding , coronavirus , covid-19 , biophysics , microbiology and biotechnology , virus , genetics , biochemistry , gene , medicine , management , disease , pathology , infectious disease (medical specialty) , economics
The recently reported “UK variant” (B.1.1.7) of SARS-CoV-2 is thought to be more infectious than previously circulating strains as a result of several changes, including the N501Y mutation. We present a 2.9-Å resolution cryo-electron microscopy (cryo-EM) structure of the complex between the ACE2 receptor and N501Y spike protein ectodomains that shows Y501 inserted into a cavity at the binding interface near Y41 of ACE2. This additional interaction provides a structural explanation for the increased ACE2 affinity of the N501Y mutant, and likely contributes to its increased infectivity. However, this mutation does not result in large structural changes, enabling important neutralization epitopes to be retained in the spike receptor binding domain. We confirmed this through biophysical assays and by determining cryo-EM structures of spike protein ectodomains bound to 2 representative potent neutralizing antibody fragments.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here